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ARTICLE

Odds of Acute Kidney Injury in Patients Receiving
Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study
Within the Department of Veterans Affairs
S. Scott Sutton1,2,*

, Joseph Magagnoli1,2, Tammy H. Cummings2 and James W. Hardin2,3

Preclinical and clinical data of dipeptidyl peptidase 4 (DPP-4) inhibitors have demonstrated discordant data regarding acute
kidney injury (AKI). Therefore, we aimed to evaluate the association between DPP-4 use and AKI. This cohort study utilized
data from the Department of Veterans Affairs evaluating patients diagnosed with type 2 (T2) diabetes with a DPP-4 inhibitor
and compared with nondiabetic and diabetic patients. The primary end point is the development of AKI, and statistical analyses were performed to examine the association. DPP-4 use is associated with a lower odds of AKI compared with diabetics
(adjusted odds ratio (OR) = 0.39; 95% confidence interval (CI) = 0.32–0.48) and nondiabetics (OR = 0.64; 95% CI = 0.52–0.79).
DPP-4 use in patients with T2 diabetes mellitus is associated with lower odds of AKI within 120 days compared with nondiabetic and diabetic controls when adjusting for study covariates.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Because the dipeptidyl peptidase 4 (DPP-4) enzyme
is expressed on non-glucagon-like peptide-1 cell types,
nondiabetes medication effects of the DPP-4 inhibitors
are possible. Preclinical and clinical data for DPP-4 inhibitors have demonstrated a nephroprotective effect;
however, clinical data have also demonstrated that DPP-4
inhibitor use was associated with a higher risk of hospitalization for acute kidney injury (AKI).
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ The purpose of this study is to evaluate patients
with type 2 diabetes mellitus with a prescription for a
DPP-4 inhibitor vs. diabetic and nondiabetic patients
and the associated odds for developing AKI. Research
question: What are the odds of AKI in patients
with diabetes receiving DPP-4 inhibitors compared

Diabetes affects more than 29 million people in the United
States, and the majority of diabetes cases are type 2 diabetes mellitus (T2DM).1 Diabetes is a risk factor for acute kidney injury (AKI), and AKI episodes may lead to electrolyte
abnormalities, pulmonary edema, chronic kidney disease,
and cardiovascular complications.2–4 Dipeptidyl peptidase
4 (DPP-4) inhibitors are a class of oral hypoglycemic medications that are used to manage patients with T2DM.5–8
DPP-4 is an enzyme expressed on the surface of most
cell types that deactivates bioactive peptides, including
1

with diabetics not receiving DPP-4 inhibitors and
nondiabetics?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ This study used a large nationwide cohort of US Veterans
to examine the association of AKI between DPP-4 inhibitors and matched control patients. This study adds additional literature to previous published discordant results.
HOW MIGHT THIS CHANGE CLINICAL PHARMA
COLOGY OR TRANSLATIONAL SCIENCE?
✔ This study can assist prescribers and payers in understanding real-world experience with this medication.
There were lower odds of AKI in the DPP-4 cohort compared with the diabetic and nondiabetic controls when
using adjusted models. However, future research should
be considered in understanding the risks and benefits of
DPP-4 use and the occurrence of AKI.

glucagon-like peptide-1 (GLP-1). DPP-4 inhibitors affect
glucose control through enhancement of glucose-dependent insulin secretion, slowed gastric emptying, and reduction of postprandial glucagon and of food intake. DPP
inhibitors are utilized as adjunctive drug therapy or monotherapy for patients inadequately controlled or who cannot
take/tolerate other oral diabetes medications. Because the
DPP-4 enzyme is also expressed on non-GLP-1 cell types,
nondiabetes medication effects of the DPP-4 inhibitors are
possible. For example, DPP-4 is also bound on the kidney
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proximal tubular cell, and microvesicle-bound DPP-4 secreted from tubular epithelial cells is found in the urine and
may be an early marker of kidney damage.9 Additionally,
renal effects of DPP-4 inhibitors may be mediated by increased GLP-1 levels.10 In addition to the pancreas, the
GLP-1 receptor is expressed in glomerular endothelial cells,
and renal effects of DPP-4 inhibitors are, in part, mediated
by GLP-1 levels.11 However, the exact role and importance
of the mechanism of kidney effects relating to the DPP-4
enzyme or DPP-4 inhibitors are not completely understood.
Preclinical and clinical data for DPP-4 inhibitors have
demonstrated a nephroprotective effect.12–15 However,
there have also been clinical data that demonstrated DPP-4
inhibitor use was associated with a higher risk of hospitalization for AKI.16 The discordant study results warrant the
need for more research evaluating DPP-4 inhibitors and
AKI. Therefore, the purpose of this study is to evaluate patients with T2DM with a prescription for a DPP-4 inhibitor
vs. diabetic and nondiabetic patients and the associated
odds for developing AKI within the Department of Veterans
Affairs (VA) Veterans Health Administration system.
METHODS
Data
This retrospective cohort study was conducted using data
from the Department of Veterans Affairs. The Veterans
Affairs Informatics and Computing Infrastructure was utilized to obtain individual-level information on demographics, administrative claims, and pharmacy dispensation. The
completeness, utility, accuracy, validity, and access methods are described on the VA website, http://www.virec.
research.va.gov. The study was conducted in compliance
with the Department of Veterans Affairs’ requirements and
received institutional review board and research and development approval. The study utilized diagnosis International
Classification of Disease 9th revision (ICD-9-CM) data
from October 1999 to September 2015, laboratory data
from January 2001 to June 2016, and pharmacy data from
December 1999 to June 2016.
Cohort selection
Cases were defined as patients who were diagnosed with
T2DM (during October 1999 to September 2015) and had
a prescription for a DPP-4 inhibitor (including sitagliptin,
saxagliptin, or linagliptin) between the dates June 2005
and February 2016. The study index period for the DPP-4
cases was the earliest date the patient was on a DPP-4 and
had an estimated glomerular filtration rate (eGFR) laboratory measure. The eGFR is a calculated laboratory from
the patients’ medical record and was captured via claims
data by Logical Observation Identifiers Names and Codes
code 33914. Nondiabetic controls were defined as patients
who never had an ICD-9-CM diagnosis of T2DM and never
had an A1c laboratory result. Uncontrolled blood sugar
was defined as an A1c value ≥7 for the nondiabetic controls. Diabetic non-DPP-4 controls were defined as those
who had a diagnosis of T2DM but never had a prescription for a DPP-4 inhibitor. To ensure adequate medical surveillance and baseline kidney function, patients who never
had an eGFR measure while on a DPP-4 were excluded.

Furthermore, controls who never had an eGFR laboratory
result during the study, June 2005 to February 2016, were
excluded.
Matching
A matching algorithm was utilized that matched DPP-4
cases to controls. A variable number of matched controls
per case was utilized, with one control being the minimum
and seven controls as a maximum. Controls were exact
matched on age at index, race, sex, and constrained controls to be within 10 mL/minute of baseline eGFR. Control
baseline eGFR measures were also required to be in the
same month and year as their matched case.
AKI outcome
Cases and controls were followed from index to 120 days
or AKI incident, whichever occurred first. Specifically, AKI
was identified from an outpatient acute kidney diagnosis
using ICD-9-CM: values were 584 (acute kidney failure),
584.5 (acute kidney failure with lesion of tubular necrosis), 584.6 (acute kidney failure with lesion of renal cortical
necrosis), 584.7 (acute kidney failure with lesion of renal
medullary necrosis), 584.8 (acute kidney failure with other
specified pathological lesion in kidney), and 584.9 (acute
kidney failure, unspecified).
Study variables
In addition to our primary predictor (DPP-4 inhibitor use),
covariates were utilized to account for possible differences
in demographic, disease burden, pharmacy, and laboratory results between the cohorts. Demographic variables
included age, sex, and race coded as white, black, other/
unknown. The Charlson comorbidity index was utilized to
account for differences in disease burden. The Charlson
index utilizes all outpatient claims for the 1 year preceding the study index. Additionally, other pharmacy medications were evaluated and included metformin use during
the follow-up period, nonsteroidal anti-inflammatory drugs
(NSAIDs), and proton pump inhibitors (PPIs).
Statistical analysis
The statistical analysis occurred in two steps. The initial step
utilized statistical tests to compare baseline characteristics
between the DPP-4 and control cohorts. For continuous
variables, such as age, eGFR, and the Charlson comorbidity index, we utilized the F-test from the analysis of variance
results. All categorical variables were analyzed using the χ2
test. In the second step, we estimated logistic regression
models to examine the association between DPP-4 use and
AKI. We estimate three models: (i) unadjusted, with only the
treatment indicator (diabetic DPP-4, diabetic non-DPP-4,
and nondiabetic); (ii) a second adjusted for the Charlson
index; and (iii) a model with all covariates (which included
treatment indicator, Charlson index, baseline eGFR, uncontrolled A1c, sex, race, age, PPI use, NSAID use, metformin use, and index year). Unadjusted odds of AKI within
120 days for comparisons between cohort groups using a
Bonferroni multiplicity adjusted interval were also tested for
each model in this step. All data management and matching
was done with SAS enterprise guide 7.1 (SAS Institute Cary,
www.cts-journal.com
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NC), and all statistical analysis was done using R (R Core
Team 2016, Vienna, Austria).
RESULTS
A total of 363,873 patients met all the study criteria. Of
these, 250,269 patients made up the nondiabetic control
group, 77,722 the diabetic non-DPP-4 group, and 35,882
the DPP-4 inhibitor cohort. Table 1 displays the summary
statistics for the three cohorts. The DPP-4 and control
cohorts are clinically similar in terms of age (66.7 (10.1)
vs. 66.8 (9.9) vs. 66.5 (10.2)), race (68% white), and sex
(96% men). The DPP-4 cohort, on average, has a lower
eGFR measure at index (69.5 (24.4) vs. 69.8 (23.3) vs. 72.2
(22.9) mL/minute). The diabetic non-DPP-4 control group,
on average, had a higher Charlson index (2.8 (2.3) vs.
2.5 (1.9) vs. 0.8 (1.5)) compared with the diabetic DPP-4
cases and nondiabetic controls. Approximately 56% of
the DPP-4 cohort had an uncontrolled A1C (defined as
A1c ≥ 7) at baseline, and 55% were on metformin during
the follow-up period. Additionally, 14% of the DPP-4 and
diabetic non-DPP-4 cohorts and 13% of the nondiabetic

control cohort had a prescription for NSAIDs, whereas
32% of both DPP-4 and diabetic non-DPP-4 cohorts
and 21% of the nondiabetic controls had a prescription
for PPIs. Of the patients on a DPP-4 inhibitor, 61.8% of
patients had a prescription for saxagliptin, 44.8% had a
prescription for sitagliptin, and 12.9% had a prescription
for linagliptin. Patients may have had a prescription for
more than one DPP-1, and as a result, the percentages do
not sum to 100.
Table 2 presents the occurrence of AKI within 120 days
for each cohort. The DPP-4 cohort had 274 incidents of AKI
equaling 7.63 (95% confidence interval (CI) = 6.74–8.52) per
1,000 people, the diabetic non-DPP-4 cohort had 21,784
incidents of AKI at 22.95 (95% CI = 21.98–24.04) incidents
per 1,000 people, and the nondiabetic cohort had 1,786 incidents of AKI equaling 7.13 (95% CI = 6.80–7.45) incidents
per 1,000 people.
The unadjusted logistic regression (Table 3, model 1)
demonstrates that patients with diabetes not on a DPP-4
inhibitor had a 3.05-fold increased odds of AKI compared
with diabetics on a DPP-4 within 120 days (odds ratio
(OR) = 3.05; 95% CI = 2.69–3.47), whereas there was no

Table 1 Patient characteristics
Diabetic non-DPP-4

Diabetic DPP-4

Nondiabetic

N = 77,722

N = 35,882

N = 250,269

66.8 (9.9)

66.7 (10.1)

66.5 (10.2)

< 0.001

Black

13,451 (17.3%)

6,009 (16.7%)

41,390 (16.5%)

< 0.001

Other/unknown

11,274 (14.5%)

5,401 (15.1%)

38,386 (15.3%)

White

52,997 (68.2%)

24,472 (68.2%)

170,493 (68.1%)

Variable
Age, mean (SD)

P value

Race

Sex
75,220 (96.8%)

34,484 (96.1%)

240,436 (96.1%)

Baseline eGFR, mean (SD)

Male

69.8 (23.3)

69.5 (24.4)

72.2 (22.9)

< 0.001
< 0.001

Charlson index, mean (SD)

2.8 (2.3)

2.5 (1.9)

0.8 (1.5)

< 0.001

Uncontrolled A1c

23,326 (30.0%)

20,194 (56.3%)

0 (0%)

< 0.001

NSAID prescription

11,013 (14.2%)

5,064 (14.1%)

33,682 (13.5%)

< 0.001

PPI prescription

25,164 (32.4%)

11,325 (31.6%)

52,263 (20.8%)

< 0.001

Metformin prescription

28,222 (36.3%)

19,742 (55.0%)

0 (0%)

< 0.001
0.24

Index year
2005

15 (0.02%)

7 (0.02%)

89 (0.03%)

2006

27 (0.035%)

13 (0.036%)

159 (0.064%)

2007

348 (0.448%)

161 (0.449%)

1,162 (0.464%)

2008

1,850 (2.38%)

864 (2.41%)

6,042 (2.41%)

2009

2,958 (3.81%)

1,367 (3.81%)

9,522 (3.805%)

2010

3,976 (5.12%)

1,840 (5.13%)

12,852 (5.14%)

2011

5,901 (7.59%)

2,700 (7.53%)

18,660 (7.46%)

2012

8,503 (10.94%)

3,926 (10.94%)

27,086 (10.82%)

2013

8,377 (10.78%)

3,864 (10.78%)

26,553 (10.61%)

2014

14,938 (19.22%)

6,897 (19.22%)

48,003 (19.18%)

2015

25,814 (33.21%)

11,923 (33.23%)

83,993 (33.56%)

2016

5,015 (6.45%)

2,320 (6.47%)

16,148 (6.45%)

DPP-4 medicationa
Saxagliptin

–

22,207 (61.8%)

–

Sitagliptin

–

16,092 (44.8%)

–

Linagliptin

–

4,664 (12.9%)

–

DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; NSAID, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.
Percentages do not equal 100 because select patients may have received different DPP inhibitors.

a
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statistically significant difference between the nondiabetic
control group and the diabetic DPP-4 users (OR = 0.93; 95%
CI = 0.82–1.06). However, the second logistic regression
model was adjusted for the Charlson comorbidity index as
a covariate and demonstrated that both diabetics not on a
DPP-4 inhibitors and nondiabetic controls were associated
with a higher odds of AKI within 120 days compared with
the diabetics on a DPP-4 (OR = 2.55; 95% CI = 2.24–2.9
and OR = 1.7; 95% CI = 1.49–1.94, respectively). This model
also revealed that as the Charlson index increases, the
odds of AKI also increase (OR = 1.38; 95% CI = 1.37–1.40).
Additionally, a third logistic regression model was utilized that
was adjusted for all study covariates and demonstrates that
diabetic non-DPP-4 inhibitors and nondiabetics are associated with a higher odds of AKI within 120 days (OR = 2.78;
95% CI = 2.43–3.17 and OR = 1.32; 95% CI = 1.14–1.53,
respectively). Model 3 also demonstrates that (i) higher values of the Charlson comorbidity index were associated with
an increase in the odds of AKI (OR = 1.26; 95% CI = 1.24–
1.27); (ii) higher baseline eGFR values are associated with
a lower odds of AKI (OR = 0.96; 95% CI = 0.96–0.96); and
(iii) compared with black patients, both white (OR = 0.76;

Table 2 Occurrence of AKI within 120 days
Cohort
Diabetic non-DPP-4
Diabetic DPP-4
Nondiabetic

Total AKI

Per 1,000 people (95% CIa)

1,784

22.95 (21.98–24.04)

274

7.63 (6.74–8.52)

1,786

7.13 (6.80–7.45)

AKI, acute kidney injury; CI, confidence interval; DPP-4, dipeptidyl peptidase 4.
Bootstrapped 95% CI.

a

95% CI = 0.70–0.83) and other/unknown (OR = 0.60; 95%
CI = 0.53–0.68) have a lower odds of AKI.
Table 4 presents the results from the unadjusted odds of
AKI within 120 days for comparisons between cohort groups
using the Bonferroni multiplicity adjusted interval. When
comparing DPP-4 cohort with diabetic non-DPP-4 controls,
we found that DPP-4 use was associated with a lower odds
AKI (unadjusted OR = 0.33; 95% CI = 0.27–0.4; adjusted
OR = 0.34; 95% CI = 0.28–0.42). Comparing the DPP-4 cohort with the nondiabetic controls, we found that the odds of
AKI in the DPP-4 cohort was not statistically significantly different in the unadjusted model (OR = 1.07, 95% CI = 0.88–
1.3), yet was statistically significant with a lower odds of AKI
within 120 days in the adjusted models (OR = 0.59, 95%
CI = 0.48–0.71 and OR = 0.64, 95% CI = 0.52–0.79). Finally,
in comparing the diabetic non-DPP-4 controls to the nondiabetic cohort, we found that the diabetic non-DPP-4 cohort had higher odds of AKI in both unadjusted (OR = 3.27;
95% CI = 2.96–3.61) and adjusted models (OR = 1.5; 95%
CI = 1.34–1.67; OR = 1.86; 95% CI = 1.65–2.1).
DISCUSSION
This retrospective analysis of US veterans compared a
national cohort of patients with T2DM and a DPP-4 inhibitor prescription with matched controls of nondiabetic patients. Patients were followed for an episode of AKI within
120 days. The goal of the study was to evaluate the association of DPP-4 inhibitor on the odds of AKI. This study found
that of the cohort groups, the diabetic non-DPP-4 control
cohort (22.95 (95% CI = 21.98–24.04) per 1,000 patients)
had the highest rate of AKI compared with the DPP-4 cohort (7.63 (95% CI = 6.74–8.52) per 1,000 patients) and the
nondiabetic control cohort (7.13 (95% CI = 6.80–7.45) per

Table 3 Odds of AKI within 120 days
Model 1
Variable

Model 2

Model 3

OR (95% CI)

OR (95% CI)

OR (95% CI)

0.01 (0.01–0.01)

0.00 (0.00–0.00)

0.38 (0.26–0.55)

Diabetic non-DPP-4

3.05 (2.69–3.47)

2.55 (2.24–2.9)

2.78 (2.43–3.17

Nondiabetic

0.93 (0.82–1.06)

1.7 (1.49–1.94)

1.32 (1.14–1.53)

(Intercept)
Diabetic DPP-4 (baseline)

Charlson index

1.38 (1.37–1.40)

1.26 (1.24–1.27)

Baseline eGFR

0.96 (0.96–0.96)

Uncontrolled A1c

0.92 (0.84–1.02)

Sex (female baseline)
Male

1.19 (0.95–1.48)

Race (black baseline)
Other/unknown
White
Age

0.6 (0.53–0.68)
0.76 (0.7–0.83)
0.98 (0.98–0.99)

PPI use

0.71 (0.66–0.77)

NSAID use

0.58 (0.49–0.68)

Metformin use

0.41 (0.35–0.48)

Index year

0.92 (0.91–0.94)

AKI, acute kidney injury; CI, confidence interval; DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; NSAID, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor.
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Table 4 Odds of AKI within 120 days: Comparisons between cohort
groups

Contrast

Model 1

Model 2

Model 3

OR (95%
CIa )

OR (95%
CIa )

OR (95%
CIa )

Diabetic DPP-4 vs.
diabetic non-DPP-4

0.33
(0.27–0.4)

0.39
(0.32–0.48)

0.34
(0.28–0.42)

Diabetic DPP-4 vs.
nondiabetic

1.07
(0.88–1.3)

0.59
(0.48–0.71)

0.64
(0.52–0.79)

Diabetic non-DPP-4
vs. nondiabetic

3.27
(2.96–3.61)

1.5
(1.34–1.67)

1.86
(1.65–2.1)

AKI, acute kidney injury; CI, confidence interval; DPP-4, dipeptidyl peptidase 4; OR, odds ratio.
Bonferroni multiplicity adjusted interval.

a

1,000 patients). Diabetic non-DPP-4 controls had higher
odds of AKI within 120 days compared with both the DPP-4
cohort and nondiabetic controls in all models. Additionally,
the unadjusted logistic regression model demonstrates that
DPP-4 inhibitors are not statistically different compared
with nondiabetic controls, and a decreased odds of AKI
compared with diabetic non-DPP-4 controls. In addition,
in the unadjusted model, diabetic non-DPP-4 cohort had
an over threefold increased odds of AKI within 120 days
compared with the nondiabetic cohort. Furthermore, the
fully adjusted model 3 demonstrated that the DPP-4 cohort
had 66% and 36% lower odds of AKI within 120 days when
compared with both control groups (diabetic non-DPP-4
and nondiabetics, respectively). Further, the diabetic nonDPP-4 cohort had an almost two fold increase in odds of
AKI within 120 days compared with the nondiabetic cohort.
Systematic reviews and meta-analyses of the safety, efficacy, and tolerance of DPP-4 inhibitors on patients with
T2DM calls for continued research and investigations on the
effects of DPP-4 inhibitor use.17–20 In a pooled analysis of randomized clinical studies of patients with T2DM on the DPP-4
inhibitor sitagliptin, the researchers concluded that the drug
was tolerable up to 76 weeks and 2 years.21,22 However, preclinical and clinical studies have focused on the association
of AKI related to DPP-4 inhibitors and have found discordant results. Preclinical animal experimental studies have
demonstrated a nephroprotective effect of DPP-4 inhibitors.
Rats given an oral dose of DPP-4 sitagliptin (200 mg/kg/
day) for 8 weeks had a renoprotective effect on their remnant kidneys.23 Diabetic rats compared with nondiabetic rats
treated with a DPP-4 inhibitor (vildagliptin) had lower body
weight, plasma insulin levels, and serum creatinine levels.
Additionally, the existence of interstitial expansion, glomerulosclerosis, and the thickening of the glomerular basement
membrane attenuated renal injury in diabetic rats administered DPP-4 inhibitors.13 DPP-4 inhibition resulted in a
dose-dependent protective effect on kidney function in a rat
model, as shown by reduced serum creatinine levels after
renal ischemia–reperfusion injury. Additionally, the reduced
serum creatinine levels were accompanied by morphological
protection indicated by a decrease in tubular necrosis.15
Select clinical evaluations have demonstrated consistent
results of the preclinical animal studies on the association

Clinical and Translational Science

of AKI with DPP-4 inhibitors. The DPP-4 inhibitor linagliptin
was not associated with increased kidney disease risk compared with placebo in individual patient-level data of pooled
analysis of 13 phase II or III clinical trials.24 DPP-4 inhibitors
were associated with reduced risk of mild and severe forms
of AKI among patients with incident diabetes in a nationally
representative cohort in Taiwan.25 Additionally, a retrospective cohort study of a large medical and pharmacy claims
database demonstrated that there was not an association
between the use of sitagliptin and AKI.26 In contrast, there
are reports of an increased association of AKI and DPP-4
inhibitors. The US Food and Drug Administration has reported episodes of acute worsening of renal function following exposure to inappropriate doses of sitagliptin in patients
with renal insufficiency where there has been inappropriate dose adjustment.27 Additionally, a nested case-control
study conducted using Taiwan’s National Health Insurance
Research Database demonstrated that those using DPP-4
inhibitors had an increased risk of AKI compared with
nonusers.16
Our study results are consistent with the preclinical animal models and clinical studies that demonstrate a protective effect of DPP-4 inhibitor use on AKI. Our study provides
value to the current literature regarding DPP-4 inhibitors and
AKI because of previous discordant results. We utilized a
different patient population to evaluate the external validity
and generalizability of previous studies. Our large sample
size utilizing matched controls provides additional evidence
that DPP-4 inhibitors may have another role in addition to
managing patients’ blood glucose levels. Although our study
has a significant number of strengths, there are several limitations that are common to claims database studies of like
methodology. Because this study was retrospective and observational, unmeasured confounders may have affected the
results, despite matching of key covariates between cohorts.
For example, there is a significant difference in the utilization
of metformin between the DPP4 and non-DPP4 cohorts.
Therefore, it is possible the patients on DPP4/metformin
could have received more stringent care, and this could
have influenced the outcome. The use of antihypertensive
medications was not evaluated, and the outcome of blood
pressure control through an antihypertensive may have had
an influence on renal outcomes. Our study variable was the
utilization of a DPP inhibitor and not the dose. However, the
dose and/or existing renal function of the patient could have
impacted the results. Specifically, the US Food and Drug
Administration has reported episodes of acute worsening
of renal function following exposure to inappropriate doses
of sitagliptin in patients with renal insufficiency where there
has been inappropriate dose adjustment.27 Additionally, the
study population was predominantly middle-to older-aged
white men; therefore, our findings may not be generalizable
to patients of different age groups or sexes. Additionally,
only the association of DPP-4 inhibitors and AKI were studied; therefore, causality or mechanisms could not be investigated. However, our association data are consistent with
previously conducted preclinical studies evaluating mechanisms. Preclinical studies suggest a glomerular and/or tubular mechanism of kidney injury; however, the exact role
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and importance of the mechanism of kidney effects relating to the DPP-4 enzyme or DPP-4 inhibitors are not completely understood. Further research is needed to continue
the evaluation of AKI in patients receiving DPP4 inhibitors to
further our understanding of the association, mechanisms,
and clinical application of AKI episodes.
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